Rapid Identification of New Biomarkers for the Classification of GM1 Type 2 Gangliosidosis Using an Unbiased <sup>1</sup>H NMR-Linked Metabolomics Strategy
Biomarkers currently available for the diagnosis, prognosis, and therapeutic monitoring of GM1 gangliosidosis type 2 (GM1T2) disease are mainly limited to those discovered in targeted proteomic-based studies. In order to identify and establish new, predominantly low-molecular-mass biomarkers for thi...
Main Authors: | Benita C. Percival, Yvonne L. Latour, Cynthia J. Tifft, Martin Grootveld |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/3/572 |
Similar Items
-
Feasibility study of cyclodextrins as active pharmaceutical ingredients for the treatment of GM1-gangliosidosis
by: Yuki Maeda, et al.
Published: (2016-02-01) -
GM1 gangliosidosis: a case report
by: Guilherme Dienstmann, et al.
Published: (2021-11-01) -
GM1 Gangliosidosis—A Mini-Review
by: Elena-Raluca Nicoli, et al.
Published: (2021-09-01) -
A feasibility study of mHealth and wearable technology in late onset GM2 gangliosidosis (Tay-Sachs and Sandhoff Disease)
by: Elin Haf Davies, et al.
Published: (2020-08-01) -
Progressive dystonia as a presenting manifestation of GM1 gangliosidosis
by: Sahil Mehta, et al.
Published: (2019-01-01)